Maintenance Therapy for Leukemia

(PREeMPT Trial)

This trial investigates the effectiveness of a personalized approach to maintenance therapy for individuals with certain blood cancers, such as leukemia, following a stem cell transplant. The goal is to determine if treatment decisions based on measurable residual disease (MRD) can improve outcomes. If doctors detect leftover cancer cells, participants may receive additional therapy. This trial suits those diagnosed with myeloid blood cancers or similar conditions who are undergoing a stem cell transplant. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in cancer care.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that maintenance therapy for some types of leukemia is often well-tolerated. For example, one study found that patients taking an oral form of this therapy had a 74.5% survival rate after 12 months. This indicates that many people can manage the treatment and continue with it. However, earlier studies found that some patients experienced too many side effects without clear benefits. Thus, while some patients do well with this therapy, others may encounter more problems.

Researchers are excited about this trial because it explores maintenance therapy options based on a patient's MRD (minimal residual disease) status, which is a new approach to treating leukemia. Unlike standard treatments that apply the same protocols to all patients, this method tailors therapy based on whether patients are MRD positive or negative. This personalized approach could lead to more effective treatments with potentially fewer side effects, as it allows doctors to decide the best course of action based on the patient's specific condition. Additionally, the trial highlights the potential to better manage leukemia by focusing on the residual disease, which is often a predictor of relapse.

Research has shown that ongoing treatment, known as maintenance therapy, can help patients with acute myeloid leukemia (AML) live longer and reduce the chance of cancer returning. In this trial, MRD-positive patients will receive maintenance therapy. One study found that patients who received maintenance therapy lived for an average of 37.8 months, compared to 15.5 months for those who did not. Another study reported that after 12 months, 72.8% of patients on maintenance therapy were still alive, compared to 55.8% of those who took a placebo. Additionally, maintenance therapy helped patients stay cancer-free for an average of 19 months, compared to 12 months without it. These findings support using maintenance therapy to help prevent relapse and extend the lives of AML patients.¹²⁶⁷⁸